enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
enGene Holdings Inc. (ENGN)
Company Research
Source: Business Wire
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer, and Raj Pruthi, M.D., Chief Medical Officer, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 10:30 a.m. ET.A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.About enGeneenGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissu
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene Holdings Inc. (NASDAQ: ENGN) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.MarketBeat
- enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $25.00 price target on the stock.MarketBeat
- enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- enGene Reports Full Year 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- enGene Reports Full Year 2024 Financial Results and Provides a Business UpdateBusiness Wire
ENGN
Sec Filings
- 12/20/24 - Form 8-K
- 12/20/24 - Form 424B5
- 12/19/24 - Form 10-K
- ENGN's page on the SEC website